AstraZeneca has agreed to purchase an additional 5.7% stake in Circassia Pharmaceuticals in a cash transaction.

AstraZeneca’s total share in the target company will increase to 19.9% from the existing 14.2%, upon completion of the transaction.

Circassia Pharmaceuticals proposes to use the proceeds for meeting research and development (R&D) expenses owed to AstraZeneca as part of a development and commercialisation agreement between the two.

The acquirer company is a UK-based biopharmaceutical company, while Circassia Pharmaceuticals is a respiratory biopharmaceutical company.

Mega Labs has acquired Laboratorios Garden House Holding.

Based in Uruguay, the acquirer company is a pharmaceutical company, while the target company is a producer of pharmaceutical medicines and supplements.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mega Labs received advisory services from Albagli Zaliasnik and Morales & Besa for the transaction.

Toho Holdings has acquired an 8.38% share in Ambicion.

“Mega Labs has acquired Laboratorios Garden House Holding.”

The transaction represents 14,000 ordinary shares in the target company.

Based in Japan, the acquirer company is involved in wholesale, dispensing pharmacy, manufacturing and pharmaceutical sales, while the target company is a developer of cancer immunotherapy through third-party share issuance.

Dipharma, Inc, the subsidiary of Italian manufacturer of active pharmaceutical ingredients Dipharma Francis, has agreed to acquire Kalexsyn within a month.

The target company will continue to operate from Kalamazoo, Michigan, US, upon completion of the acquisition. David Zimmermann and Robert Gadwood, the founders of the target company, will continue to manage the new entity, following the acquisition.

Based in the US, the target company is a contract research organisation.

Chinese pharmaceutical products manufacturer and developer Livzon Pharmaceutical Group plans to sell its share in a pharmaceuticals company based in Guangdong from the existing 92.14% to 77.14%.

The company plans to divest the 15% share for CNY66.2m ($10.49m).